TLIS vs. BNGO, ASTC, SMIT, TBIO, SPEC, THMO, HTGMQ, OLITW, PRENW, and QSIAW
Should you be buying Talis Biomedical stock or one of its competitors? The main competitors of Talis Biomedical include Bionano Genomics (BNGO), Astrotech (ASTC), Schmitt Industries (SMIT), Telesis Bio (TBIO), Spectaire (SPEC), ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), OmniLit Acquisition (OLITW), Prenetics Global (PRENW), and Quantum-Si (QSIAW). These companies are all part of the "measuring and control equipment" industry.
Talis Biomedical vs. Its Competitors
Talis Biomedical (NASDAQ:TLIS) and Bionano Genomics (NASDAQ:BNGO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.
Bionano Genomics has a consensus price target of $7.00, indicating a potential upside of 131.79%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Talis Biomedical.
Talis Biomedical has a net margin of 0.00% compared to Bionano Genomics' net margin of -294.05%. Talis Biomedical's return on equity of -79.74% beat Bionano Genomics' return on equity.
In the previous week, Bionano Genomics had 9 more articles in the media than Talis Biomedical. MarketBeat recorded 9 mentions for Bionano Genomics and 0 mentions for Talis Biomedical. Bionano Genomics' average media sentiment score of 0.77 beat Talis Biomedical's score of 0.00 indicating that Bionano Genomics is being referred to more favorably in the news media.
Talis Biomedical has higher earnings, but lower revenue than Bionano Genomics. Talis Biomedical is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
43.8% of Talis Biomedical shares are held by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are held by institutional investors. 46.0% of Talis Biomedical shares are held by company insiders. Comparatively, 0.9% of Bionano Genomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Talis Biomedical has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500.
Summary
Talis Biomedical and Bionano Genomics tied by winning 8 of the 16 factors compared between the two stocks.
Get Talis Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLIS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TLIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talis Biomedical Competitors List
Related Companies and Tools
This page (NASDAQ:TLIS) was last updated on 8/15/2025 by MarketBeat.com Staff
MarketBeat All Access